Masking Strategies for the Bioorthogonal Release of Anticancer Glycosides

Belén Rubio-ruiz; Thomas L. Bray; Ana Perez-Lopez; Asier Unciti-broceta

doi:10.1007/978-3-319-65587-1_12

Masking Strategies for the Bioorthogonal Release of Anticancer Glycosides

Belén Rubio-ruiz, Thomas L. Bray, Ana Perez-Lopez, Asier Unciti-broceta

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract / Description of output

Significant progress in the bioorthogonal field has resulted in the advent of a new type of prodrug: bioorthogonal prodrugs, i.e. metabolically stable precursors of therapeutic agents that are specifically activated by non-native, non-biological, non-perturbing physical or chemical stimuli. The application of such unique drug precursors in conjunction with their corresponding activating source is under preclinical experimentation as a novel way to elicit site-specific activation of cytotoxic drugs, with particular emphasis on anticancer glycosides. In this chapter, the strategies developed for the masking and bioorthogonal release of cytotoxic nucleosides using benign electromagnetic radiations, biocompatible click chemistry and bioorthogonal organometallic (BOOM) catalysis will be discussed in detail.

Original language	English
Title of host publication	Coupling and Decoupling of Diverse Molecular Units in Glycosciences
Editors	Zbigniew J. Witczak, Roman Bielski
Publisher	Springer
Pages	269-298
ISBN (Electronic)	978-3-319-65587-1
ISBN (Print)	978-3-319-65586-4
DOIs	https://doi.org/10.1007/978-3-319-65587-1_12
Publication status	Published - 21 Nov 2017

Access to Document

10.1007/978-3-319-65587-1_12

Cite this

@inbook{84d6a1ba3a84455e865f35456bf001a5,

title = "Masking Strategies for the Bioorthogonal Release of Anticancer Glycosides",

abstract = "Significant progress in the bioorthogonal field has resulted in the advent of a new type of prodrug: bioorthogonal prodrugs, i.e. metabolically stable precursors of therapeutic agents that are specifically activated by non-native, non-biological, non-perturbing physical or chemical stimuli. The application of such unique drug precursors in conjunction with their corresponding activating source is under preclinical experimentation as a novel way to elicit site-specific activation of cytotoxic drugs, with particular emphasis on anticancer glycosides. In this chapter, the strategies developed for the masking and bioorthogonal release of cytotoxic nucleosides using benign electromagnetic radiations, biocompatible click chemistry and bioorthogonal organometallic (BOOM) catalysis will be discussed in detail.",

author = "Bel{\'e}n Rubio-ruiz and Bray, {Thomas L.} and Ana Perez-Lopez and Asier Unciti-broceta",

year = "2017",

month = nov,

day = "21",

doi = "10.1007/978-3-319-65587-1_12",

language = "English",

isbn = "978-3-319-65586-4",

pages = "269--298",

editor = "Witczak, {Zbigniew J.} and Roman Bielski",

booktitle = "Coupling and Decoupling of Diverse Molecular Units in Glycosciences",

publisher = "Springer",

}

TY - CHAP

T1 - Masking Strategies for the Bioorthogonal Release of Anticancer Glycosides

AU - Rubio-ruiz, Belén

AU - Bray, Thomas L.

AU - Perez-Lopez, Ana

AU - Unciti-broceta, Asier

PY - 2017/11/21

Y1 - 2017/11/21

N2 - Significant progress in the bioorthogonal field has resulted in the advent of a new type of prodrug: bioorthogonal prodrugs, i.e. metabolically stable precursors of therapeutic agents that are specifically activated by non-native, non-biological, non-perturbing physical or chemical stimuli. The application of such unique drug precursors in conjunction with their corresponding activating source is under preclinical experimentation as a novel way to elicit site-specific activation of cytotoxic drugs, with particular emphasis on anticancer glycosides. In this chapter, the strategies developed for the masking and bioorthogonal release of cytotoxic nucleosides using benign electromagnetic radiations, biocompatible click chemistry and bioorthogonal organometallic (BOOM) catalysis will be discussed in detail.

AB - Significant progress in the bioorthogonal field has resulted in the advent of a new type of prodrug: bioorthogonal prodrugs, i.e. metabolically stable precursors of therapeutic agents that are specifically activated by non-native, non-biological, non-perturbing physical or chemical stimuli. The application of such unique drug precursors in conjunction with their corresponding activating source is under preclinical experimentation as a novel way to elicit site-specific activation of cytotoxic drugs, with particular emphasis on anticancer glycosides. In this chapter, the strategies developed for the masking and bioorthogonal release of cytotoxic nucleosides using benign electromagnetic radiations, biocompatible click chemistry and bioorthogonal organometallic (BOOM) catalysis will be discussed in detail.

U2 - 10.1007/978-3-319-65587-1_12

DO - 10.1007/978-3-319-65587-1_12

M3 - Chapter

SN - 978-3-319-65586-4

SP - 269

EP - 298

BT - Coupling and Decoupling of Diverse Molecular Units in Glycosciences

A2 - Witczak, Zbigniew J.

A2 - Bielski, Roman

PB - Springer

ER -

Masking Strategies for the Bioorthogonal Release of Anticancer Glycosides

Abstract / Description of output

Access to Document

Fingerprint

Cite this